
Opinion|Videos|May 16, 2025
Strategies to Minimize Toxicities, and the Pharmacist’s Role in Educating and Supporting Patients With NSCLC
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how to minimize EGFR tyrosine kinase inhibitor (TKI) adverse effects through preventive measures such as maintaining good skin regimens with moisturizers and SPF 30+ sunscreen, prescribing topical steroids and antibiotics for skin rash, and managing diarrhea with hydration, diet modifications, and loperamide.
Advertisement
Episodes in this series

Management Strategies for EGFR TKI Adverse Effects: Summary for Physicians
Dermatologic Toxicity Management
- Proactive skin care regimen before initiating EGFR TKIs:
- Recommend non–alcohol-based creamy moisturizers (morning and night)
- Daily SPF 30+ sunscreen on exposed areas
- Encourage protective clothing (hats, long sleeves)
- Treatment options for acneiform rash:
- Topical steroids
- Topical clindamycin gel
- Oral doxycycline (helps reduce severity and prevent superimposed infection)
- Consider dermatology referral for severe cases
Diarrhea Management
- Patient education:
- Instruct patients to monitor and track stool frequency above baseline
- Emphasize adequate hydration
- Dietary modifications:
- Recommend BRAT-style diet (bananas, rice, apples, toast)
- Low-fiber, bland foods
- Avoid dairy, greasy, and fatty foods
- Pharmacologic intervention:
- Provide step-by-step loperamide (Imodium) dosing instructions
- Review medication list for potential exacerbating agents
- Instruct patients to hold laxatives/stool softeners during diarrhea episodes
Clinical Pearls
- Male patients may require additional encouragement regarding skin care regimens
- Emphasize importance of patient communication between visits
- Always perform medication reconciliation to identify potential contributory medications
- Ensure patients have clear instructions for all prescribed treatments
This approach focuses on proactive management to minimize adverse events while maintaining treatment efficacy.
Advertisement
Related to this article

SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.

On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.

A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.

Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.

Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.

The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5



